AUREALIS THERAPEUTICS
DEAD

Serial Number

98113572

Owner

Aurealis Therapeutics AG

Attorney

R. Glenn Schroeder

Filing Date

Aug 2, 2023

Add to watchlist:

No watchlists yet
View on USPTO

AUREALIS THERAPEUTICS Trademark

Serial Number: 98113572

AUREALIS THERAPEUTICS is a trademark filed by Aurealis Therapeutics AG on August 2, 2023. The trademark is classified under Class 5 (Pharmaceuticals). The application is currently no longer active.

Owner Contact Info

Aurealis Therapeutics AG

Hochbergerstrasse 60C
Basel 4057 , CH

Entity Type: 25

Trademark Details

Filing Date

August 2, 2023

Registration Date

Not Registered

Published for Opposition

August 13, 2024

Goods & Services

Pharmaceutical and veterinary preparations, namely, for tissue regeneration, treatment of chronic inflammatory diseases as well as autoimmune disorders and cancer; sanitary preparations for medical purposes, namely, for tissue regeneration, treatment of chronic inflammatory diseases as well as autoimmune disorders and cancer; dietetic food and substances, namely, fermented milk products, drinks and gum, adapted for medical or veterinary use; dietary supplements for humans and animals; health care products, namely, medical plasters, medical dressings, medicated ointments, medicated sprays, vaccine preparations, and human therapeutic agents for tissue regeneration, treatment of chronic inflammatory diseases as well as autoimmune disorders and cancer; disinfectants; preparations for destroying vermin; fungicides and herbicides; pharmaceuticals, biosimilars, medicine, drugs, namely, immunomodulators and anticancer agents, antibodies, antibody fragments, checkpoint inhibitors and checkpoint modifiers, vaccines, for human beings and animals; prokaryotic organisms, namely, genetically modified bacteria, bacteria producing growth factors, antibodies, immunomodulators, anticancer agents, checkpoint inhibitors and checkpoint modifiers and vaccines for medical use; medicines for human purposes, namely, for tissue regeneration, treatment of chronic inflammatory diseases as well as autoimmune disorders and cancer; medicines for veterinary purposes, namely, for tissue regeneration, treatment of chronic inflammatory diseases as well as autoimmune disorders and cancer; bacteriological preparations for medical and veterinary use, namely, for tissue regeneration, treatment of chronic inflammatory diseases as well as autoimmune disorders and cancer; biological preparations for medical purposes, namely, for tissue regeneration, treatment of chronic inflammatory diseases as well as autoimmune disorders and cancer; biological preparations for veterinary purposes, namely, for tissue regeneration, treatment of chronic inflammatory diseases as well as autoimmune disorders and cancer; chemical preparations for medical purposes, namely, for tissue regeneration, treatment of chronic inflammatory diseases as well as autoimmune disorders and cancer; chemical preparations for pharmaceutical purposes, namely, for tissue regeneration, treatment of chronic inflammatory diseases as well as autoimmune disorders and cancer; chemical preparations for veterinary purposes, namely, for tissue regeneration, treatment of chronic inflammatory diseases as well as autoimmune disorders and cancer; pharmaceutical and veterinary preparations and substances in particular for the treatment of cancer, inflammatory diseases, immune system related diseases, specifically autoimmune disorders, and other conditions which can be treated or ameliorated by antibodies or antibody fragments binding to, activating or blocking of a target antigen or ameliorated by immunomodulating factors, namely, for tissue regeneration, treatment of chronic inflammatory diseases as well as autoimmune disorders and cancer

Filing History

ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED
Nov 10, 2025 MAB6
ABANDONMENT - NO USE STATEMENT FILED
Nov 10, 2025 ABN6
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Mar 24, 2025 EXRA
SOU EXTENSION 1 GRANTED
Mar 23, 2025 EX1G
SOU EXTENSION 1 FILED
Mar 23, 2025 EXT1
SOU TEAS EXTENSION RECEIVED
Mar 23, 2025 EEXT
NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Oct 8, 2024 NOAM
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Aug 13, 2024 NPUB
PUBLISHED FOR OPPOSITION
Aug 13, 2024 PUBO
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Jul 24, 2024 NONP
APPROVED FOR PUB - PRINCIPAL REGISTER
Jul 8, 2024 CNSA
TEAS/EMAIL CORRESPONDENCE ENTERED
Jul 3, 2024 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Jul 3, 2024 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Jul 3, 2024 TROA
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Apr 4, 2024 GNRN
NON-FINAL ACTION E-MAILED
Apr 4, 2024 GNRT
NON-FINAL ACTION WRITTEN
Apr 4, 2024 CNRT
ASSIGNED TO EXAMINER
Apr 3, 2024 DOCK
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Aug 7, 2023 NWOS
NEW APPLICATION ENTERED
Aug 5, 2023 NWAP